An observational study in Intracerebral Hemorrhage (ICH), sponsored by University Hospital, Tours. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.
Among the 24 studies in Cerebral Hemorrhage with a site in France, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2026, is one of 11 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 23rd registered.
458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.
Browse Cerebral Hemorrhage studies →11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Tours · Sites in France
Ages 18+
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1990; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 300 across 181 observational studies indexed under Cerebral Hemorrhage.
Median enrollment 300 across the 13 interventional studies, 455 across the 11 observational. Of the 13 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 24 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 2 studies filed under Cerebral Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Hemorrhage with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781034Centre Hospitalier Universitaire de NīmesDescriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies | 2026-12 |
| NCT06802588University Hospital, ToursOptimization of the Management of Non-Traumatic Intracerebral Hemorrhage (OPT-ICH) | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies in Cerebral Hemorrhage with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will establish a prospective, multicenter national cohort of patients with spontaneous intracerebral hemorrhage (ICH). A standardized multimodal database integrating clinical, biological, and imaging data will be collected.
The study aims to better characterize ICH patient phenotypes, identify diagnostic and prognostic biomarkers, and describe adherence to evidence-based acute management strategies, including the proportion of patients managed according to the care bundle validated in the INTERACT 3 study.
The cohort is also intended to provide a structured platform for translational research and the preparation of future stratified interventional clinical trials in spontaneous ICH.
This prospective, multicenter national cohort study in ICH is designed to support comprehensive clinical, biological, imaging, and process-of-care characterization of patients.
A centralized and harmonized biobank will be established to enable the collection and analysis of biological samples, with a focus on biomarkers related to inflammation, hematoma resorption, and genetic susceptibility.
A standardized and interoperable imaging database will be implemented to allow quantitative analysis of hemorrhagic lesions, including hematoma volume, hematoma expansion, perihematomal edema, and their temporal evolution over time.
The study will also document acute ICH management practices, including the proportion of patients managed according to the evidence-based care bundle validated in the INTERACT 3 study. Components of this bundle include early intensive blood pressure control, reversal of anticoagulation when applicable, maintenance of blood glucose within recommended targets, body temperature control, and systematic neurosurgical consultation. Adherence to these components will be recorded as part of routine care.
The cohort will rely on a network of participating clinical and research centers trained and equipped to apply standardized procedures for patient inclusion, data collection, imaging acquisition, and biospecimen handling, with the objective of promoting harmonized clinical practice and high-quality data generation.
Finally, the cohort is intended to serve as a structured platform to support the design and implementation of future stratified interventional clinical trials in spontaneous ICH, based on phenotypic, biomarker, imaging, and care-process data generated within the cohort.
Adult patients with spontaneous intracerebral hemorrhage included in 4 centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intracerebral hemorrhage secondary to another identified condition, including:
Number of patients enrolled in the TIPITCH registry with a data completion rate ' ≥ 80% across the three main components of the registry, defined as:
* Clinical data (sociodemographic characteristics, medical history, clinical examination, severity scores, and treatments); * Imaging data (at least one centralized and analyzable neuroimaging examination); * Biological data (at least one biological sample centralized in the biobank according to predefined quality standards).
Time frame: From inclusion through completion of baseline data collection (during index hospitalization)
Proportion of patients managed according to the care bundle validated in the INTERACT 3 study, including the following components:
* Early intensive blood pressure control; * Reversal of anticoagulation when applicable; * Maintenance of blood glucose within recommended targets (6.1-7.8 mmol/L for non-diabetic patients; 7.8-10.0 mmol/L for diabetic patients); * Body temperature \< 37.5 °C within one hour of hospital admission; * Systematic neurosurgical consultation.
Time frame: Baseline
Number of stored biological samples, by sample type
Number of stored biological samples, by sample type (including citrated plasma, heparinized plasma, serum, DNA) and meeting predefined quality criteria
Time frame: Through study completion, an average of ten years
Volume of stored biological samples, by sample type
Volume of stored biological samples, by sample type (including citrated plasma, heparinized plasma, serum, DNA) and meeting predefined quality criteria
Time frame: Through study completion, an average of ten years
Number of centralized and analyzable brain imaging studies
Number of centralized and analyzable brain imaging studies, by imaging modality (CT, MRI), sequences, and availability of associated metadata.
Time frame: Through study completion, an average of ten years
Completion rate of clinical follow-up data
Completion rate of clinical follow-up data, including the modified Rankin Scale (mRS), at 3, 6, and 24 months after intracerebral hemorrhage.
Time frame: Through study completion, an average of ten years
Number of participating centers achieving a data collection quality level > 80% across the three registry components (clinical, imaging, and biological data).
Number of participating centers achieving a data collection quality level \> 80% across the three registry components (clinical, imaging, and biological data).
Time frame: Through study completion, an average of ten years
Number of research projects initiated or scientific publications produced using data from the TIPITCH registry.
Number of research projects initiated or scientific publications produced using data from the TIPITCH registry.
Time frame: Through study completion, an average of ten years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2036, 120 months after the start.
Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 120 months is above that.
Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.